$5.40
▲ +1.1% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive (AQST) Q2 2026 Earnings Call Transcript
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ...
Overview
52-week range
$2.93
$7.55
53% of range
Avg surprise (last 3)
+10.3%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
102%
EM ±15.9% · $5 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.18 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.07 | $-0.14 | +50.0% | +70.8% | -0.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.14 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.14 | $-0.18 | +22.2% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.24 | $-0.17 | -41.2% | — | +2.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.13 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.03 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.17 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.03 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.10 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.11 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $14M | — | $13M | $10M | $9M | — | $14M |
| Cost of revenue | $4M | $3M | — | $5M | $5M | $4M | — | $4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-8M | $-4M | — | $-11M | $-11M | $-19M | — | $-8M |
| Net income | $-23M | $-8M | — | $-15M | $-14M | $-23M | — | $-12M |
| EPS (diluted) | $-0.18 | $-0.07 | — | $-0.14 | $-0.14 | $-0.24 | — | $-0.13 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $98M | $111M | $121M | $129M | $61M | $69M | $72M | $78M |
| Inventory | $7M | $8M | $6M | $8M | $8M | $7M | $6M | $7M |
| Total current assets | $118M | $130M | $149M | $152M | $82M | $89M | $88M | $97M |
| Total assets | $132M | $141M | $160M | $164M | $94M | $102M | $101M | $110M |
| Long-term debt | $55M | $45M | — | $45M | $45M | $45M | — | $45M |
| Total liabilities | $189M | $175M | $194M | $168M | $166M | $163M | $162M | $155M |
| Total equity | $-57M | $-34M | $-34M | $-4M | $-73M | $-61M | $-60M | $-45M |